Stockscreener 앱 받기
0.6962
7.96%
-0.0602
Outlook Therapeutics Inc 주식(OTLK)의 최신 뉴스
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Yahoo Finance
Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - Moomoo
Outlook Therapeutics Posts Q3 Financials, Raises Funds for Lytenava Launch - VisionMonday.com
Outlook Therapeutics Inc (OTLK) Stock News Today - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
MSN Money - MSN
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
Outlook Therapeutics CEO Robert Jahr acquires shares and warrants for $0 - Investing.com South Africa
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet - Yahoo Finance
Outlook Therapeutics CFO Kenyon acquires 101,010 shares By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) CEO purchases 151,515 shares and matching warrants - Stock Titan
Outlook Therapeutics, Inc. 2026 Q3ResultsEarnings Call Presentation (NASDAQ:OTLK) 2026-08-14 - Seeking Alpha
Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares By Investing.com - Investing.com Australia
Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares - Investing.com
Outlook Therapeutics CFO Kenyon acquires 101,010 shares - Investing.com
Outlook Therapeutics (OTLK) investor GMS Ventures reports 16.4% beneficial stake - Stock Titan
Outlook Therapeutics (OTLK) insider-linked entity buys 2.5M shares plus 2.5M warrants - Stock Titan
Outlook Therapeutics (OTLK) CFO Lawrence Kenyon buys 101K shares plus 101K warrants - Stock Titan
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
OTLK Q3 FY2026 earnings call - finance.biggo.com
Outlook Therapeutics to Report Q3 After $55 Million Stock Sale Sends Shares Tumbling - finance.biggo.com
Friday's session: most active stocks - ChartMill
OTLK Reiterated by BTIG -- Price Target Maintained at $4.00 - GuruFocus
Oncobiologics Q3 Earnings Call Highlights - MarketBeat
Earnings call transcript: Outlook Therapeutics narrows loss in Q3 2026 as launch nears - Investing.com
Outlook Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
OTLK: FDA-approved LYTENAVA targets rapid U.S. launch and $500M+ peak sales by 2030 - TradingView
Outlook Therapeutics Announces $55 Million Equity Offering - TipRanks
Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call - benzinga.com
Outlook Therapeutics, Inc. (OTLK) Stock Forecasts - Yahoo! Finance Canada
Outlook Therapeutics (OTLK) Q3 Earnings Miss Highlight Valuation Challenges - GuruFocus
Q3 2026 Outlook Therapeutics Inc Earnings Call Transcript - GuruFocus
Form 8K OUTLOOK THERAPEUTICS INC For: 14 August By Investing.com - Investing.com Nigeria
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Outlook Therapeutics reports Q3 FY2026 net loss $20.3M, adjusted loss $10.9M; readies U.S. launch of LYTENAVA - TradingView
Outlook Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 - marketscreener.com
Outlook Therapeutics reports Q3 loss, targets late 2026 launch By Investing.com - Investing.com Nigeria
Outlook Therapeutics reports Q3 loss, targets late 2026 launch - Investing.com
Outlook Therapeutics Q3 net loss narrows slightly as costs drop - TradingView
FDA-approved LYTENAVA targets wet AMD; U.S. launch planned by year-end 2026 - Stock Titan
Outlook Therapeutics Q3 Results: Loss narrows to 8 cents per share - scanx.trade
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most - benzinga.com
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants - mx.advfn.com
These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - stocktwits.com
Outlook Therapeutics (OTLK) Stock Forum and Discussion - Moomoo
Outlook Therapeutics faces financial challenges ahead of Q3 earnings with expected loss and recent stock offering. - Pluang
Outlook Therapeutics (OTLK) Q3 Earnings Preview: Valuation Chall - GuruFocus
Outlook Therapeutics' $55 Million Rescue: A Dilution Trade-Off on the Road to LYTENAVA's US Launch - AD HOC NEWS
Why is Outlook Therapeutics stock plunging today? By Investing.com - Investing.com South Africa
Why is Outlook Therapeutics stock plunging today? - Investing.com Nigeria
Top Premarket Decliners - marketscreener.com
Outlook Therapeutics Prices $55 Million Securities Offering; Shares Down Pre-Bell - Moomoo
Why Did OTLK Stock Crash In Pre-Market Today? - Yahoo Finance
2.24%
1.78%
자본화:
|
볼륨(24시간):